louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT06020170: Delving Into Participation Patterns in Social Anxiety Studies
Official title: Delving Into Participation Patterns in Social Anxiety Clinical Trials and Investigating Engagement Trends Among Individuals Impacted by the Disease
Study type: OBSERVATIONAL
Overall status: NOT_YET_RECRUITING
Conditions: Social Anxiety
Keywords: social anxiety
Lead sponsor: Power Life Sciences Inc.
Sponsor class: INDUSTRY
First posted: 2023-08-31
Enrollment: 500
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CROSSOVER
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: People with social anxiety who are actively considering enrolling in an observational clinical trial, but have not yet completed enrollment and randomization.

Brief summary: The study seeks to delve into the firsthand experiences of patients diagnosed with social anxiety who partake in a separate clinical trial featuring a specific medical intervention. The primary emphasis will be on meticulously tracking the rates of trial completion and withdrawal among these individuals.

By joining this clinical trial, individuals have the unique opportunity to contribute to the betterment of future social anxiety patients and play an active role in advancing medical research.


Eligibility criteria: Inclusion Criteria:

* Patient has self-identified as planning to enroll in a clinical trial
* Patient has been diagnosed with social anxiety
* Patient is a minimum of 18 years or older

Exclusion Criteria:

* Patient does not understand, sign, and return consent form
* Inability to perform regular electronic reporting
* Patient is pregnant

Primary outcomes:
measure: Number of patients who decide to participate in a social anxiety clinical trial
timeFrame: 3 months
measure: Rate of patients who remain in social anxiety clinical trial to trial completion
timeFrame: 12 months
Secondary outcomes:
Other outcomes:
Locations:
city: San Francisco
country: United States
facility: Power Life Sciences
state: California
Study officials:
affiliation: Power Life Sciences Inc.
name: Michael B Gill
role: STUDY_DIRECTOR
References:
citation: Alvi T, Kumar D, Tabak BA. Social anxiety and behavioral assessments of social cognition: A systematic review. J Affect Disord. 2022 Aug 15;311:17-30. doi: 10.1016/j.jad.2022.04.130. Epub 2022 Apr 28.
citation: Gao J, Feng Y, Xu S, Wilson A, Li H, Wang X, Sun X, Wang Y. Appearance anxiety and social anxiety: A mediated model of self-compassion. Front Public Health. 2023 Mar 21;11:1105428. doi: 10.3389/fpubh.2023.1105428. eCollection 2023.
citation: Fancourt D, Steptoe A, Bu F. Trajectories of anxiety and depressive symptoms during enforced isolation due to COVID-19 in England: a longitudinal observational study. Lancet Psychiatry. 2021 Feb;8(2):141-149. doi: 10.1016/S2215-0366(20)30482-X. Epub 2020 Dec 9.
Clinical trial NCT04254770: At-Home Care for Subjects With Periodontitis
Official title: A Randomized, Parallel-design Study to Evaluate the Effects of Home Use of the Sonicare Powered Toothbrush and a Manual Toothbrush on Subjects With Periodontitis
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Periodontitis
Dental Plaque
Lead sponsor: Philips Clinical & Medical Affairs Global
Sponsor class: INDUSTRY
First posted: 2020-02-05
Enrollment: 346
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The effect of use of powered toothbrushing in patients exhibiting periodontal inflammation has been observed repeatedly in clinical studies conducted over a 20+ year period. Whether these subjects also had periodontitis, or not, was not a collected data metric as it was outside the scope of the Investigation. This study, therefore, will specifically include and document that a subject exhibits periodontitis upon study entry, and measure the ensuing response following professional treatment of scaling and root planing, followed by home use of the assigned study products (powered or manual toothbrushing).


Eligibility criteria: Inclusion Criteria:

* Between the ages of 18-75 years
* Exhibiting Stage I or II periodontitis
* Minimum of 20 'scorable' teeth (excluding 3rd molars)
* Regular manual toothbrush user
* Have a minimum average plaque score of \> 1.8 per Modified Plaque Index scoring with 3-6 hours plaque accumulation
* Agree to desist use of interproximal cleaning aids and other prohibited devices or medicaments during the study period
* Be a non-smoker (\> 10 years), or never smoker

Exclusion Criteria:

* Have a cardiac pacemaker or implanted cardiac defibrillator
* Have uncontrolled Insulin-Dependent Diabetes Have current use of antibiotic medications or use within 4 weeks of enrollment
* Have current use of prescription-dose anti-inflammatory medications or anticoagulants Have excessive gingival recession, per Investigator/Examiner discretion
* Have heavy deposits of calculus, either supragingival and/or subgingival, per Investigator/Examiner discretion
* Have had a professional prophylaxis within 4 weeks of the study
* Prior chemotherapy, immunotherapy or radiation therapy within last 10 years

Primary outcomes:
measure: Change in symptoms of inflammation of the periodontium, as measured by Bleeding on Probing.
timeFrame: 6 months
Secondary outcomes:
measure: Change in supragingival plaque, as measured by Modified Plaque Index
timeFrame: 6 months
measure: Change in clinical attachment level
timeFrame: 6 months
measure: Change in periodontitis, as measured by probing pocket depth
timeFrame: 6 months
Other outcomes:
Locations:
city: Fort Wayne
country: United States
facility: Salus Research, Inc
state: Indiana
Study officials:
References:
Clinical trial NCT05072470: Benefits of Assistive Listening Device for Speech Intelligibility
Official title: Benefits of an Assistive Listening Device for Speech Intelligibility in Noise
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Hearing Loss
Lead sponsor: Sonova AG
Sponsor class: INDUSTRY
Collaborators: name: Hearts for Hearing
First posted: 2021-10-11
Enrollment: 10
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: OTHER

Brief summary: Speech intelligibility in noise will be evaluated in adults with moderate to moderate-severe sensorineural hearing loss, using an assistive listening device and hearing aid, and compared to speech intelligibility in noise using hearing aids alone.


Eligibility criteria: Inclusion Criteria:

* adults age 18 or older with bilateral moderate to moderate severe sensorineural hearing loss, pure tone average must be between 40 and 69 dB HL (decibel Hearing Level)
* experienced hearing aid users
* symmetric hearing loss (no more than 15 dB difference between the ears at three contiguous frequencies)
* good written and spoken English language skills
* healthy outer ear as confirmed by otoscopy

Exclusion Criteria:

* contradictions to medical device noted upon otoscopy
* known hypersensitivity or allergy to materials of investigational device or comparator
* inability to produce reliable test results
* known psychological problems
* self reported symptoms of dizziness or vertigo

Primary outcomes:
measure: Speech Intelligibility in Noise
timeFrame: Day 1 of a one day study
Secondary outcomes:
Other outcomes:
Locations:
city: Oklahoma City
country: United States
facility: Hearts for Hearing
state: Oklahoma
Study officials:
References:
Clinical trial NCT06915870: Comparison of Empagliflozin and Dapagliflozin in Patients With Heart Failure Taking Standard Treatment
Official title: Comparison of Empagliflozin and Dapagliflozin in Patients With Heart Failure Taking Standard Treatment
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Diabetes Mellitus
Heart Failure
Keywords: ejection fraction
angiotensin receptor neprilysin inhibitor
Dapagliflozin
Empagliflozin
Lead sponsor: Sheikh Zayed Medical College
Sponsor class: OTHER_GOV
First posted: 2025-04-08
Enrollment: 108
Sex: ALL
Minimum age (years): 40
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Participants were enrolled and randomly divided in two groups. In group A, participants were prescribed Dapagliflozin 10 mg daily. In group B, participants were prescribed Empagliflozin 10 mg daily. All participants were followed-up in OPD after 12 weeks for assessment of ejection fraction.

Detailed description: This study's rationale is to examine the effects of dapagliflozin and empagliflozin on heart failure in patients receiving ARNI and SGLT2. Research revealed that the two medications results are identical. Although the cardiac functioning improved better with empagliflozin. But limited data has been available in this regard, while no local trial conducted before. Thus, in routine SGLT2 and ARNI are given to control glycemic level and maintain cardiac functioning. However, addition of Empagliflozin and Dapagliflozin can be more beneficial in improving cardiac functioning and reducing adverse events. Therefore the investigators planned to conduct this study to get evidence in local population. This will help to improve practice.

Eligibility criteria: Inclusion Criteria:

* Patients aged 40-60 years of either gender diagnosed with heart failure ( Heart failure was defined as presence of ejection fraction \<50% on echocardiography, with pedal edema, water in lungs, paroxysmal nocturnal dyspnea or exertional limitation due to failure of ventricular fillings)
* Diabetic patients, with HBA1c\>6.5% for \>1 year already taking SGLT-2 and ARNI inhibitor.

Exclusion Criteria:

* Patients already had valvular device, mitral or aortic valve regurgitation or stenosis detected on echocardiography, heart transplantation, chronic renal failure or dialysis patients, cardiomyopathy, liver failure or malignancy.
* Patients already taking trial drugs or other anti-glycemic or cardiac medication.

Primary outcomes:
measure: Comparison of Empagliflozin and Dapagliflozin in heart failure in diabetic patients taking Sodium-glucose cotransporter-2 and angiotensin receptor neprilysin inhibitor
timeFrame: 12 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Lahore
country: Pakistan
facility: Shaikh Zayed Hospital
state: Punjab
Study officials:
References:
Clinical trial NCT00786370: Dexmedetomidine vs. Propofol for Cataract Surgery
Official title: Dexmedetomidine vs. Propofol for Monitored Anesthesia Care During Cataract
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Cataract
Keywords: propofol
dexmedetomidine
cataract
respiratory
blood pressure
Cataract surgery
Lead sponsor: The Cooper Health System
Sponsor class: OTHER
First posted: 2008-11-06
Enrollment: 24
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The use of dexmedetomidine in cataract surgery is still limited and to date only one study has examined anesthetic technique in this patient population. This pilot study will therefore compare the use of dexmedetomidine and propofol in subjects undergoing cataract surgery. The primary endpoint will be based on simple cardiorespiratory measures often associated with complications from sedation as well as assessment of the achieved sedation by the attending anesthesiologist and surgeon.


Eligibility criteria: Inclusion Criteria:

1. Normal renal function
2. No chronic use of narcotics
3. ASA PS1-3
4. Males or females age 18 or older

Exclusion Criteria:

1. Liver disease (Child Pugh classification 1-3)
2. History of chronic use of sedatives, narcotics, alcohol or illicit drugs or allergy to any the study medications
3. History of 1st and 2nd degree heart block (not paced)
4. Any patient with EF \< 30%
5. Patients with active seizure history
6. Pregnant patients (women of child bearing potential will have a preoperative pregnancy test as is standard of practice)

Primary outcomes:
measure: To compare select cardiorespiratory effects of dexmedetomidine sedation to those of propofol sedation in patients undergoing cataract surgery.
timeFrame: 1 day
Secondary outcomes:
Other outcomes:
Locations:
city: Camden
country: United States
facility: Cooper University Hospital
state: New Jersey
Study officials:
affiliation: The Cooper Health System
name: Jeffrey Littman, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06038175: vHIT Testing for Presentation of Dizziness at a Comprehensive Stroke Center
Official title: Is Video Head Impulse Testing a Safe, Reliable and Cost Effective Method of Assessment of Patients Presenting for Dizziness at a Comprehensive Stroke Center?
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Stroke, Acute
Vertigo
Vertigo, Peripheral
Dizziness
Dizziness; Syndrome
Lead sponsor: Medical University of South Carolina
Sponsor class: OTHER
First posted: 2023-09-14
Enrollment: 30
Sex: ALL
Minimum age (years): 18
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: DIAGNOSTIC

Brief summary: The purpose of this study is to evaluate the sensitivity and specificity of the video head impulse test (vHIT) device, when implemented in the acute ED setting to identify acute ischemic stroke or central pathology vs peripheral vestibular dysfunction in patient's presenting with vertigo. This study will evaluate the implementation of the device, consistency with current diagnostic standards, unnecessary administration of antithrombolytics and will further study the reduction in hospital admissions and overall healthcare costs.

Detailed description: In the proposed study, subjects admitted to the Emergency Department (ED) with symptoms of dizziness, concerning for an acute ischemic stroke, will undergo routine triage (bedside neurologic examination, head impulse testing, CT scan) and will then be tested with a vHIT device to attempt to further identify the cause of dizziness, after standard of care testing has been performed. The clinician performing the vHIT will be blinded to the result of the CT scan before entering their report.

Eligibility criteria: Inclusion Criteria:

* Adults between the ages of 18-90
* Admitted to the MUSC ED with symptomatic dizziness, concerning for a stroke vs peripheral vestibular dysfunction.

Exclusion Criteria:

* Prisoners
* COVID +
* Cognitively Impaired Individuals

Primary outcomes:
measure: Sensitivity & Specificity of vHIT device
timeFrame: This will be performed once all results are compiled, not to exceed 90 days after study completion.
Secondary outcomes:
measure: Time to perform testing
timeFrame: From time the study team member arrives to patient's location until vHIT testing is complete, not to exceed 1 hour.
measure: Predictive Value
timeFrame: At the time results are compared from vHIT testing to CT scan, not to exceed 30 days post testing.
measure: Cost Analysis
timeFrame: This will be performed once all results are compiled, not to exceed 90 days after study completion.
Other outcomes:
Locations:
city: Charleston
country: United States
facility: Medical University of South Carolina
state: South Carolina
Study officials:
References:
Clinical trial NCT06875375: The Role of Probiotic LH76 in Human Gut Health
Official title: A Clinical Study on the Safety and Efficacy of Probiotic LH76 in Modulating Gut Microbiota and Enhancing Intestinal Health in Healthy Adults
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: Gut Microbiota Modulation
Lead sponsor: Wecare Probiotics Co., Ltd.
Sponsor class: INDUSTRY
First posted: 2025-03-13
Enrollment: 50
Sex: ALL
Minimum age (years): 18
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study aims to evaluate the safety and efficacy of the probiotic LH76 as a dietary supplement in healthy adults. The research will assess its effects on gut microbiota composition, intestinal health, and immune function compared to a placebo. Key outcomes include changes in microbial diversity, intestinal barrier integrity, and immune response markers over the intervention period. The findings will contribute to understanding the potential health benefits of LH76 and its role in supporting gut and immune health.


Eligibility criteria: Inclusion Criteria:

1. Willing to undergo 3 follow-up visits during the intervention period Be willing to provide blood, urine and stool samples 2 times during the intervention period
2. Willing to self-administer probiotic or placebo once a day during the intervention period
3. Good eyesight, can read and write, can wear glasses
4. Have good hearing and be able to hear and understand all instructions during the intervention

Exclusion Criteria:

1. Digestive diseases, mainly gastrointestinal diseases (celiac disease, ulcerative colitis, Crohn's disease)
2. Have a serious neurological condition (epilepsy, stroke, severe head trauma, meningitis in the last 10 years, brain surgery, brain tumor, prolonged coma - not including general anaesthesia)
3. Have received/are receiving treatment for the following mental disorders: alcohol/drug/substance abuse dependence, schizophrenia, psychosis, bipolar disorder
4. Take medication for depression or low mood Internal organ failure (heart, liver or kidney failure, etc.)
5. Have received radiation or chemotherapy in the past
6. Have undergone a general anesthesia procedure/procedure within the past three years, or plan to undergo a general anesthesia procedure/procedure within the next 3 months during this trial period
7. Have had hepatitis (hepatitis B, hepatitis C), HIV or syphilis in the past Open Contacts/Locations

Primary outcomes:
measure: Changes in Gut Microbiota Composition in Response to LH76 Supplementation
timeFrame: Week 0 and Week 8
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT00424775: A Study of Carboplatin + Paclitaxel and MK0683 in Patients With Chemotherapy-naive Non-Small Cell Lung Cancer (NSCLC)(0683-066)
Official title: A Phase I Study of Carboplatin + Paclitaxel and MK0683 in Patients With Chemotherapy-naive Non-Small Cell Lung Cancer (NSCLC)
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE1
Conditions: Neoplasms
Keywords: Non-Small Cell Lung Cancer (NSCLC)
Lead sponsor: Merck Sharp & Dohme LLC
Sponsor class: INDUSTRY
First posted: 2007-01-22
Enrollment: 3
Sex: ALL
Minimum age (years): 20
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The clinical study will evaluate safety, tolerability and Pharmacokinetics of MK0683 in combination with carboplatin and paclitaxel in chemotherapy-naive NSCLC patients.


Eligibility criteria: Inclusion Criteria:

* Chemotherapy-naive patients who are histologically or cytologically diagnosed NSCLC with stage IIIB (not applicable of radical thoracic radiation) or stage IV
* Patients with normal organ function and bone marrow function

Exclusion Criteria:

* Given radical thoracic radiation for NSCLC or radiation for other than original lesion within 3 weeks
* Any peripheral neuropathy above grade 2
* Any ascites, pleural effusion or pericardiac effusion which requires treatment
* Any uncontrolled concomitant illness
* Pregnant or breast-feeding

Primary outcomes:
measure: Number of Participants With a Dose Limited Toxicity at First Cycle
timeFrame: 25 Days (first cycle)
Secondary outcomes:
measure: Area Under the Curve (AUC(0-24 hr)) at Day 4
timeFrame: Day 4
measure: Area Under the Curve (AUC(0-24 hr)) at Day 5
timeFrame: Day 5
measure: Maximum Concentration (Cmax) at Day 4
timeFrame: Day 4
measure: Maximum Concentration (Cmax) at Day 5
timeFrame: Day 5
Other outcomes:
Locations:
Study officials:
affiliation: Merck Sharp & Dohme LLC
name: Medical Monitor
role: STUDY_DIRECTOR
References:
Clinical trial NCT04801875: Cervical Pain and Exercise in Musicians
Official title: Effectiveness of the Selected Exercise Program on Non-specific Cervical Pain in Ney and Violin Performers
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Cervical Pain
Keywords: Exercise
Cervical Pain
Disabilities
Musicians
Lead sponsor: Hasan Kalyoncu University
Sponsor class: OTHER
First posted: 2021-03-17
Enrollment: 40
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: This study was based on pre-test and post-test methods. Musicians who met inclusion criterion were assigned to violin and ney groups according to performing musical instrument.
Primary purpose: TREATMENT

Brief summary: Exercise training that is one of the effective treatment methods for cervical pain, is crucial in developing mobility and stability. Exercise training significantly reduces cervical pain as it advances postural alignment and neuromuscular coordination. In many single group studies on cervical pain in violin performers, it has been reported that the stabilization exercises have favorable consequences on pain relief and postural correction. But, there are no studies comparing ney and violin performers and analyzing the effectiveness of exercise training on non-specific cervical pain. The aim of this study is to search the effects of selected exercise training on pain, disability, range of motion, flexibility, strength and quality of life in ney and violin performers with non-specific cervical pain.


Eligibility criteria: Inclusion Criteria:

* Being professional musicians
* Using violin or ney musical instruments
* Had non-specific cervical pain during 3 months

Exclusion Criteria:

* Had cervical surgery in the last 3 months, discogenic pain, radiculopathy, neurological or systemic disorders,
* Missing exercise training session more than 2

Primary outcomes:
measure: Pain intensity
timeFrame: 8 weeks
measure: Functional Status
timeFrame: 8 weeks
measure: Life Quality
timeFrame: 8 weeks
Secondary outcomes:
measure: Muscle Strength
timeFrame: 8 weeks
measure: Grip Strength
timeFrame: 8 weeks
measure: Range of Motion
timeFrame: 8 weeks
measure: Spinal Mobility
timeFrame: 8 weeks
Other outcomes:
Locations:
city: Gaziantep
country: Turkey
facility: Hasan kalyoncu üniversity
Study officials:
References:
citation: Chan C, Driscoll T, Ackermann B. Development of a specific exercise programme for professional orchestral musicians. Inj Prev. 2013 Aug;19(4):257-63. doi: 10.1136/injuryprev-2012-040608. Epub 2012 Dec 4.
citation: Kuo YL, Lee TH, Tsai YJ. Evaluation of a Cervical Stabilization Exercise Program for Pain, Disability, and Physical Impairments in University Violinists with Nonspecific Neck Pain. Int J Environ Res Public Health. 2020 Jul 28;17(15):5430. doi: 10.3390/ijerph17155430.
citation: Ackermann B, Driscoll T, Kenny DT. Musculoskeletal pain and injury in professional orchestral musicians in Australia. Med Probl Perform Art. 2012 Dec;27(4):181-7.